Netherlands buys Cervarix
This article was originally published in Scrip
Executive Summary
GlaxoSmithKlinewill supply its cervical cancer vaccine Cervarix to the Dutch national immunisation programme, which aims to vaccinate all 12-year-old girls. A catch-up programme for girls aged 13-16 will begin next year. GSK estimates that 350,000 girls will be vaccinated with Cervarix in the first year.
You may also be interested in...
Cervarix link to UK girl's death "unlikely"
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Generic Topamax launched in European markets
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
NICE confirms limits on Alimta for lung cancer
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.